跳至主要内容
临床试验/ACTRN12622000537752
ACTRN12622000537752已完成未知

Exploring the activity of pseudoephedrine in treating retrograde ejaculation following retroperitoneal lymph node dissection (RPLND) in survivors of testicular cancer - Part A

Peter MacCallum Cancer Centre0 个研究点目标入组 52 人开始时间: 2022年4月6日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
52

研究概览

简要总结

n/a

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 o limit(—)
性别
Male

入选标准

  • Participants must meet all the following criteria for study entry:
  • 1.Participant has provided written, informed consent OR electronic, informed consent sighted by an investigator, on Telehealth.
  • 2.Males greater than or equal to 18 years at time of informed consent.
  • 3.Histologically confirmed testicular germ cell tumour (based on archival tissue report)
  • 4.Retroperitoneal lymph node dissection for management of testicular cancer at least six months prior to consent.
  • 5.Participant is willing and able to comply with the protocol for the duration of the study including treatment, and scheduled visits and examination including follow up.

排除标准

  • Participants who meet any of the following criteria will be excluded from study entry:
  • 1.Currently receiving treatment or planning to receive treatment within two months (i.e., surgery, chemotherapy, radiotherapy) for testicular cancer (or other malignancy).
  • 2.Known medical condition or other issue that in the opinion of the investigator, that would affect adherence to study requirements.

研究者

发起方
Peter MacCallum Cancer Centre

相似试验